World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
14304
World Ranking
9199
National Ranking
4076

John P. Clancy publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where John P. Clancy sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 237 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

John P. Clancy D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where John P. Clancy sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 65 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

John P. Clancy is affiliated with the Cystic Fibrosis Foundation in the United States. Their research primarily focuses on the field of Medicine, with a particular emphasis on Pulmonary and Respiratory Medicine.

Their work covers a variety of related subfields, including Physiology, Emergency Medical Services, Genetics, and Speech and Hearing. The main topics addressed in their publications include:

  • Cystic Fibrosis Research Advances
  • Neonatal Respiratory Health Research
  • Asthma and respiratory diseases
  • Pediatric health and respiratory diseases
  • Hearing, Cochlea, Tinnitus, Genetics
  • Hearing Loss and Rehabilitation
  • Child Nutrition and Feeding Issues

John P. Clancy has contributed multiple papers to various scientific journals. Notable recent publications include:

  • Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials (2022), published in The Lancet Respiratory Medicine
  • Tbx2 is a master regulator of inner versus outer hair cell differentiation (2022), published in Nature
  • PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy (2021), published in Journal of Cystic Fibrosis
  • Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design (2021), published in Annals of the American Thoracic Society
  • Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study (2020), published in Journal of Cystic Fibrosis

Their frequent co-authors include Rhonda D. Szczesniak, Emrah Gecili, David P. Nichols, Cole Brokamp, and Teresa Pestian. John P. Clancy's publications appear frequently in these venues:

  • Journal of Cystic Fibrosis
  • bioRxiv (Cold Spring Harbor Laboratory)
  • American Journal of Respiratory and Critical Care Medicine
  • UNC Libraries
  • The Lancet Respiratory Medicine

Best Publications

  • Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

    Frank J. Accurso;Steven M. Rowe;J. P. Clancy;Michael P. Boyle

  • Recombinant human acid α-glucosidase Major clinical benefits in infantile-onset Pompe disease

    P. S. Kishnani;D. Corzo;M. Nicolino;B. Byrne

  • Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

    J. P. Clancy;Steven M. Rowe;Frank J. Accurso;Moira L. Aitken

  • A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

    Amit Gaggar;Patricia L. Jackson;Brett D. Noerager;Philip J. O’Reilly

  • SUPPRESSION OF A CFTR PREMATURE STOP MUTATION IN A BRONCHIAL EPITHELIAL CELL LINE

    David M. Bedwell;Anisa Kaenjak;Dale J. Benos;Zsuzsa Bebok

  • Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

    Richard B. Moss;David Rodman;L. Terry Spencer;Moira L. Aitken

  • Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

    Richard B Moss;Carlos Milla;John Colombo;Frank Accurso

  • Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis

    J. P. Clancy;Zsuzsa Bebök;Fadel Ruiz;Chris King

  • Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

    J P Clancy;L Dupont;M W Konstan;J Billings

  • Early Treatment with Alglucosidase Alfa Prolongs Long Term Survival of Infants with Pompe Disease

    Priya S. Kishnani;Deya Corzo;Nancy D. Leslie;Daniel Gruskin

  • A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis.

    F. E. Ruiz;J. P. Clancy;M. A. Perricone;Z. Bebok

  • A macromolecular complex of β2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA

    Anjaparavanda P. Naren;Bryan Cobb;Chunying Li;Koushik Roy

  • “CFTR Modulator Theratyping: Current Status, Gaps and Future Directions”

    John Paul Clancy;Calvin U. Cotton;Scott H. Donaldson;George M. Solomon

  • Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation

    Gavin M. Braunstein;Richard M. Roman;John P. Clancy;Brian A. Kudlow

  • Airway microbiota across age and disease spectrum in cystic fibrosis

    Edith T. Zemanick;Brandie D. Wagner;Brandie D. Wagner;Charles E. Robertson;Richard C. Ahrens

  • Failure of cAMP agonists to activate rescued ΔF508 CFTR in CFBE41o– airway epithelial monolayers

    Zsuzsa Bebok;James F. Collawn;John Wakefield;William Parker

  • Cigarette Smoke Induces Systemic Defects in Cystic Fibrosis Transmembrane Conductance Regulator Function

    S. Vamsee Raju;Patricia L. Jackson;Clifford A. Courville;Carmel M. McNicholas

  • Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients

    Amit Gaggar;Yao Li;Nathaniel Weathington;Margaret Winkler

  • Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data

    Frank J. Accurso;Fredrick Van Goor;Jiuhong Zha;Anne J. Stone

  • Clinical Effectiveness of Elexacaftor/Tezacftor/Ivacaftor in People with Cystic Fibrosis.

    David P Nichols;David P Nichols;Alex C Paynter;Sonya L. Heltshe;Sonya L. Heltshe;Scott H Donaldson

Frequent Co-Authors

Steven M. Rowe
Steven M. Rowe University of Alabama at Birmingham
Eric J. Sorscher
Eric J. Sorscher Emory University
Michael W. Konstan
Michael W. Konstan Case Western Reserve University
Amit Gaggar
Amit Gaggar University of Alabama at Birmingham
Bonnie W. Ramsey
Bonnie W. Ramsey University of Washington
Richard B. Moss
Richard B. Moss Stanford University
Felix Ratjen
Felix Ratjen University of Toronto
J. Edwin Blalock
J. Edwin Blalock University of Alabama at Birmingham
Joseph M. Pilewski
Joseph M. Pilewski University of Pittsburgh
Namasivayam Ambalavanan
Namasivayam Ambalavanan University of Alabama at Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing John P. Clancy

Trending Scientists

Recently Published Articles